Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
7.1M
Short interest
settlement 2026-09-30
4.5
Days to cover
-1.4 days vs prior
40.0%
Short share of volume
2026-10-23
15,212
Fails to deliver
settlement 2026-09-04
Wed 28 Oct
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-23.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in FULC is 7,110,810 shares, up 94,647 shares over the last month. Over the last 48 readings it ranged from 2,994,328 shares (15 December 2025) to 7,994,430 shares (29 May 2026). At the reported average volume of 1.6M shares a day that is 4.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/fulc" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 7,110,810 | -1.2% | 1,587,423 | 4.48 |
| 2026-09-15 | 7,194,912 | +2.5% | 1,226,440 | 5.87 |
| 2026-08-31 | 7,016,163 | +5.4% | 2,067,223 | 3.39 |
| 2026-08-14 | 6,656,924 | +0.4% | 1,329,924 | 5.01 |
| 2026-07-31 | 6,632,184 | -4.0% | 1,462,153 | 4.54 |
| 2026-07-15 | 6,911,811 | +7.6% | 1,730,477 | 3.99 |
| 2026-06-30 | 6,425,180 | +16.3% | 4,329,743 | 1.48 |
| 2026-06-15 | 5,524,373 | -30.9% | 5,921,022 | 1.00 |
| 2026-05-29 | 7,994,430 | +2.5% | 403,603 | 19.81 |
| 2026-05-15 | 7,799,579 | -2.1% | 574,218 | 13.58 |
| 2026-04-30 | 7,967,121 | +5.5% | 855,927 | 9.31 |
| 2026-04-15 | 7,553,337 | +8.5% | 784,424 | 9.63 |
| 2026-03-31 | 6,962,035 | +41.1% | 1,501,711 | 4.64 |
| 2026-03-13 | 4,932,604 | +17.1% | 1,202,637 | 4.10 |
| 2026-02-27 | 4,210,945 | +19.7% | 1,104,191 | 3.81 |
| 2026-02-13 | 3,518,354 | -9.1% | 468,766 | 7.51 |
| 2026-01-30 | 3,872,332 | +7.9% | 750,360 | 5.16 |
| 2026-01-15 | 3,588,926 | +9.8% | 784,657 | 4.57 |
| 2025-12-31 | 3,268,648 | +9.2% | 864,733 | 3.78 |
| 2025-12-15 | 2,994,328 | -21.3% | 3,866,199 | 1.00 |
| 2025-11-28 | 3,806,493 | +6.8% | 966,028 | 3.94 |
| 2025-11-14 | 3,564,671 | +1.1% | 618,942 | 5.76 |
| 2025-10-31 | 3,525,229 | -0.7% | 683,148 | 5.16 |
| 2025-10-15 | 3,550,355 | +6.0% | 452,563 | 7.84 |
| 2025-09-30 | 3,349,875 | -9.2% | 616,825 | 5.43 |
| 2025-09-15 | 3,687,485 | -0.9% | 405,059 | 9.10 |
| 2025-08-29 | 3,721,073 | -36.1% | 396,686 | 9.38 |
| 2025-08-15 | 5,823,141 | +16.0% | 601,670 | 9.68 |
| 2025-07-31 | 5,020,641 | +2.1% | 1,165,187 | 4.31 |
| 2025-07-15 | 4,917,362 | -12.8% | 606,136 | 8.11 |
| 2025-06-30 | 5,638,853 | -3.1% | 675,134 | 8.35 |
| 2025-06-13 | 5,820,117 | +2.4% | 351,745 | 16.55 |
| 2025-05-30 | 5,681,558 | +15.3% | 677,454 | 8.39 |
| 2025-05-15 | 4,928,661 | +44.9% | 1,093,748 | 4.51 |
| 2025-04-30 | 3,402,692 | -4.5% | 364,371 | 9.34 |
| 2025-04-15 | 3,563,358 | -4.5% | 332,651 | 10.71 |
| 2025-03-31 | 3,733,393 | -28.5% | 407,335 | 9.17 |
| 2025-03-14 | 5,219,364 | +6.2% | 477,443 | 10.93 |
| 2025-02-28 | 4,915,414 | +10.6% | 391,284 | 12.56 |
| 2025-02-14 | 4,444,304 | +2.6% | 369,864 | 12.02 |
| 2025-01-31 | 4,331,841 | -7.3% | 462,988 | 9.36 |
| 2025-01-15 | 4,674,470 | +10.4% | 615,300 | 7.60 |
| 2024-12-31 | 4,233,740 | -0.5% | 1,482,700 | 2.86 |
| 2024-12-13 | 4,256,506 | -7.2% | 782,077 | 5.44 |
| 2024-11-29 | 4,584,670 | -2.0% | 925,233 | 4.96 |
| 2024-11-15 | 4,678,092 | -5.9% | 883,007 | 5.30 |
| 2024-10-31 | 4,970,723 | -10.0% | 588,477 | 8.45 |
| 2024-10-15 | 5,520,543 | -6.4% | 671,667 | 8.22 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 23 October 2026, the short share of FULC volume is 40.0%, down 25.9 points over the last five sessions. Over the last 30 readings it ranged from 22.4% (22 October 2026) to 74.5% (15 September 2026). The latest reading is 9.4 points below the 30-session average of 49.3%, on 246K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-23 | 98K | 246K | 40.0% | 0 |
| 2026-10-22 | 185K | 827K | 22.4% | 0 |
| 2026-10-21 | 129K | 205K | 62.9% | 0 |
| 2026-10-20 | 53K | 151K | 35.4% | 0 |
| 2026-10-19 | 143K | 292K | 49.2% | 0 |
| 2026-10-16 | 149K | 227K | 65.8% | 0 |
| 2026-10-15 | 106K | 181K | 58.6% | 11 |
| 2026-10-14 | 246K | 435K | 56.5% | 50 |
| 2026-10-13 | 315K | 446K | 70.7% | 0 |
| 2026-10-12 | 103K | 169K | 61.0% | 0 |
| 2026-10-09 | 147K | 308K | 47.8% | 0 |
| 2026-10-08 | 157K | 433K | 36.3% | 0 |
| 2026-10-07 | 113K | 222K | 50.7% | 0 |
| 2026-10-06 | 148K | 242K | 61.0% | 318 |
| 2026-10-05 | 151K | 268K | 56.4% | 0 |
| 2026-10-02 | 228K | 452K | 50.6% | 0 |
| 2026-10-01 | 144K | 247K | 58.4% | 0 |
| 2026-09-30 | 134K | 568K | 23.7% | 0 |
| 2026-09-29 | 292K | 784K | 37.3% | 5 |
| 2026-09-28 | 174K | 277K | 62.9% | 30,300 |
| 2026-09-25 | 320K | 999K | 32.0% | 0 |
| 2026-09-24 | 247K | 547K | 45.1% | 0 |
| 2026-09-23 | 127K | 426K | 29.7% | 0 |
| 2026-09-22 | 103K | 295K | 34.8% | 0 |
| 2026-09-21 | 100K | 170K | 59.1% | 0 |
| 2026-09-18 | 162K | 286K | 56.7% | 0 |
| 2026-09-17 | 160K | 325K | 49.0% | 66 |
| 2026-09-16 | 128K | 329K | 38.8% | 0 |
| 2026-09-15 | 288K | 387K | 74.5% | 20,000 |
| 2026-09-14 | 83K | 160K | 52.2% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 4 September 2026, the fails-to-deliver balance in FULC is 15,212 shares, down 1,903 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (5 June 2026) to 129,760 shares (18 June 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-04 | 15,212 | $3.84 | $58K |
| 2026-08-20 | 17,115 | $3.91 | $67K |
| 2026-08-18 | 36,029 | $3.84 | $138K |
| 2026-08-14 | 10,494 | $3.71 | $39K |
| 2026-08-11 | 890 | $3.75 | $3K |
| 2026-08-06 | 17,629 | $3.77 | $66K |
| 2026-08-04 | 500 | $3.71 | $2K |
| 2026-07-17 | 14,091 | $3.50 | $49K |
| 2026-06-30 | 353 | $3.73 | $1K |
| 2026-06-29 | 2,756 | $3.80 | $10K |
| 2026-06-18 | 129,760 | $3.50 | $454K |
| 2026-06-15 | 514 | $3.45 | $2K |
| 2026-06-11 | 19,389 | $3.51 | $68K |
| 2026-06-09 | 459 | $3.44 | $2K |
| 2026-06-08 | 11,884 | $3.69 | $44K |
| 2026-06-05 | 2 | $3.37 | $7 |
| 2026-05-13 | 46 | $6.96 | $320 |
| 2026-04-30 | 3 | $7.15 | $21 |
| 2026-04-24 | 10 | $8.08 | $81 |
| 2026-04-20 | 652 | $8.29 | $5K |
| 2026-03-12 | 1,203 | $7.79 | $9K |
| 2026-02-27 | 937 | $8.73 | $8K |
| 2026-01-30 | 72 | $10.94 | $788 |
| 2026-01-29 | 15 | $10.48 | $157 |
| 2026-01-23 | 1,572 | $11.05 | $17K |
| 2026-01-20 | 12,500 | $10.14 | $127K |
| 2026-01-09 | 20,649 | $10.11 | $209K |
| 2026-01-05 | 27 | $10.92 | $295 |
| 2025-12-22 | 3,900 | $12.28 | $48K |
| 2025-12-18 | 77 | $12.08 | $930 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for FULC in the last 90 days. The most recent filings are listed below. Latest filing: TANG KEVIN (10% owner) on 2026-07-17.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-17 | TANG KEVIN | 10% owner | Buy | 51K | $3.52 | $179K | 7.1M |
| 2026-07-16 | TANG KEVIN | 10% owner | Buy | 117K | $3.56 | $415K | 7.0M |
| 2026-07-15 | TANG KEVIN | 10% owner | Buy | 107K | $3.56 | $382K | 6.9M |
| 2026-07-14 | TANG KEVIN | 10% owner | Buy | 76K | $3.58 | $272K | 6.8M |
| 2026-07-14 | TANG KEVIN | 10% owner | Buy | 54K | $3.56 | $191K | 6.7M |
| 2026-07-13 | TANG KEVIN | 10% owner | Buy | 13K | $3.54 | $46K | 6.7M |
| 2026-06-26 | Ezekowitz Alan | Director | Sell | 18K | $3.65 | $66K | 11K |
| 2026-02-02 | Gould Robert J | Director | Sell | 15K | $10.72 | $161K | 455K |
| 2026-01-02 | Gould Robert J | Director | Sell | 15K | $10.87 | $163K | 470K |
| 2026-01-02 | Gould Robert J | Director | Sell | 15K | $11.87 | $178K | 470K |
| 2025-12-15 | Oltmans Curtis Gale | Chief Legal Officer | Sell | 3K | $12.92 | $45K | 10K |
| 2025-12-08 | RA Capital Healthcare Fund LP | TenPercentOwner | Sell | 2.7M | $14.28 | $38.6M | 6.1M |
| 2025-12-08 | RA Capital Healthcare Fund LP | TenPercentOwner | Sell | 92K | $14.98 | $1.4M | 6.1M |
| 2025-12-08 | RA Capital Healthcare Fund LP | TenPercentOwner | Sell | 1.4M | $13.33 | $18.4M | 8.9M |
| 2025-12-08 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 92K | $14.98 | $1.4M | 6.1M |
| 2025-12-08 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 2.7M | $14.28 | $38.6M | 6.1M |
| 2025-12-08 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 1.4M | $13.33 | $18.4M | 8.9M |
| 2025-11-19 | Gould Robert J | Director | Sell | 15K | $11.03 | $165K | 485K |
| 2025-05-08 | Tourangeau Greg | Principal Accounting Officer | Sell | 498 | $5.06 | $3K | 14K |
| 2024-08-21 | Shah Rajeev M. | TenPercentOwner | Other transaction | 8.5M | price not stated in the filing | not stated | 3.1M |
| 2024-07-03 | Sapir Alex | See Remarks | Exercise or conversion | 150K | $3.27 | $491K | 193K |
| 2024-05-07 | Tourangeau Greg | Principal Accounting Officer | Sell | 236 | $7.76 | $2K | 12K |
| 2024-03-08 | Tourangeau Greg | Vice President, Finance | Sell | 5K | $11.72 | $57K | 12K |
| 2024-03-04 | Sapir Alex | See Remarks | Buy | 43K | $11.35 | $492K | 43K |
| 2023-05-10 | Tourangeau Greg | Principal Accounting Officer | Sell | 210 | $3.31 | $695 | 16K |
| 2023-01-20 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Buy | 1.9M | $13.00 | $25.0M | 11.6M |
| 2023-01-13 | Gould Robert J | Interim President & CEO | Sell | 7K | $15.00 | $101K | 500K |
| 2023-01-04 | RA Capital Healthcare Fund LP | TenPercentOwner | Buy | 122K | $7.03 | $860K | 9.6M |
| 2023-01-04 | RA Capital Healthcare Fund LP | TenPercentOwner | Buy | 58K | $7.80 | $455K | 9.7M |
| 2022-12-27 | Kolchinsky Peter | TenPercentOwner | Buy | 4K | $5.99 | $24K | 9.5M |
| 2022-12-19 | Kolchinsky Peter | TenPercentOwner | Buy | 99K | $5.90 | $583K | 9.5M |
| 2022-12-16 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Buy | 1.3M | $5.42 | $7.3M | 9.4M |
| 2022-12-15 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Buy | 237K | $5.50 | $1.3M | 8.1M |
| 2022-12-14 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Buy | 825K | $5.46 | $4.5M | 7.8M |
| 2022-12-13 | TRV GP III, LLC | TenPercentOwner | Other transaction | 2.0M | price not stated in the filing | not stated | 2.0M |
| 2022-06-07 | Gould Robert J | Director | Exercise or conversion | 71K | $7.84 | $560K | 578K |
| 2022-06-07 | Gould Robert J | Director | Sell | 71K | $8.09 | $578K | 507K |
| 2022-06-06 | Gould Robert J | Director | Exercise or conversion | 24K | $7.84 | $191K | 531K |
| 2022-06-06 | Gould Robert J | Director | Sell | 24K | $8.10 | $197K | 507K |
| 2022-06-03 | Gould Robert J | Director | Exercise or conversion | 26K | $7.84 | $200K | 532K |
| 2022-06-03 | Gould Robert J | Director | Sell | 26K | $7.95 | $203K | 507K |
| 2022-06-02 | Gould Robert J | Director | Exercise or conversion | 17K | $7.84 | $131K | 523K |
| 2022-06-02 | Gould Robert J | Director | Sell | 17K | $7.92 | $132K | 507K |
| 2022-05-06 | Tourangeau Greg | Controller | Grant | 3K | $0.00 | $0 | 16K |
| 2022-04-07 | Gould Robert J | Director | Exercise or conversion | 6K | $7.84 | $44K | 512K |
| 2022-04-07 | Gould Robert J | Director | Sell | 6K | $24.02 | $135K | 507K |
| 2022-04-05 | Gould Robert J | Director | Exercise or conversion | 53K | $7.84 | $412K | 559K |
| 2022-04-05 | Gould Robert J | Director | Sell | 53K | $24.26 | $1.3M | 507K |
| 2022-04-04 | Gould Robert J | Director | Exercise or conversion | 7K | $7.84 | $57K | 514K |
| 2022-04-04 | Gould Robert J | Director | Sell | 7K | $24.02 | $174K | 507K |
| 2022-04-01 | Gould Robert J | Director | Sell | 34K | $24.03 | $828K | 507K |
| 2022-04-01 | Gould Robert J | Director | Exercise or conversion | 34K | $7.84 | $270K | 541K |
| 2021-11-10 | STARR KEVIN P | TenPercentOwner | Other transaction | 1.0M | price not stated in the filing | not stated | 4.0M |
| 2021-11-10 | LEVIN MARK J | Director,TenPercentOwner | Other transaction | 1.0M | price not stated in the filing | not stated | 4.0M |
| 2021-09-22 | STARR KEVIN P | TenPercentOwner | Other transaction | 1.0M | price not stated in the filing | not stated | 5.0M |
| 2021-09-22 | LEVIN MARK J | Director,TenPercentOwner | Other transaction | 1.0M | price not stated in the filing | not stated | 5.0M |
| 2021-08-11 | Stuart Bryan | See Remarks | Sell | 28K | $23.75 | $665K | 0 |
| 2021-08-11 | Stuart Bryan | See Remarks | Exercise or conversion | 28K | $7.84 | $220K | 28K |
| 2021-08-10 | Stuart Bryan | See Remarks | Exercise or conversion | 32K | $7.84 | $251K | 32K |
| 2021-08-10 | Stuart Bryan | See Remarks | Sell | 32K | $17.50 | $560K | 0 |
| 2021-08-10 | Moxham Christopher | Chief Scientific Officer | Exercise or conversion | 21K | $7.84 | $162K | 21K |
| 2021-08-10 | Moxham Christopher | Chief Scientific Officer | Sell | 21K | $17.00 | $352K | 0 |
| 2021-08-10 | Moxham Christopher | Chief Scientific Officer | Exercise or conversion | 31K | $7.84 | $244K | 31K |
| 2021-08-10 | Moxham Christopher | Chief Scientific Officer | Sell | 31K | $18.00 | $559K | 0 |
| 2021-06-28 | GERAGHTY JAMES A | Director | Buy | 10K | $9.16 | $92K | 91K |
| 2021-06-28 | Oltmans Curtis Gale | SVP, General Counsel | Buy | 1K | $9.01 | $10K | 1K |
| 2021-06-28 | Thomson Peter G. | VP Finance & Accounting | Buy | 2K | $9.00 | $21K | 2K |
| 2021-06-28 | Morabito Christopher | Chief Medical Officer | Buy | 1K | $9.16 | $10K | 1K |
| 2021-03-16 | Gould Robert J | See Remarks | Sell | 789 | $12.43 | $10K | 507K |
| 2021-03-15 | Gould Robert J | See Remarks | Sell | 9K | $12.13 | $112K | 507K |
| 2021-02-22 | Thomson Peter G. | VP Finance & Accounting | Sell | 5K | $14.72 | $74K | 15K |
| 2021-02-22 | Thomson Peter G. | VP Finance & Accounting | Exercise or conversion | 5K | $7.84 | $39K | 20K |
| 2021-02-16 | Gould Robert J | See Remarks | Sell | 2K | $14.56 | $24K | 517K |
| 2021-02-16 | Gould Robert J | See Remarks | Sell | 7K | $14.19 | $93K | 518K |
| 2021-01-21 | Thomson Peter G. | VP Finance & Accounting | Sell | 7K | $14.00 | $92K | 15K |
| 2021-01-20 | Gould Robert J | See Remarks | Sell | 10K | $12.08 | $121K | 525K |
| 2020-09-14 | Wallace Owen B. | Chief Scientific Officer | Exercise or conversion | 6K | $7.84 | $50K | 133K |
| 2020-07-08 | Gould Robert J | See Remarks | Sell | 3K | $20.00 | $50K | 535K |
| 2020-07-08 | Wallace Owen B. | Chief Scientific Officer | Sell | 3K | $20.00 | $59K | 127K |
| 2020-07-08 | Wallace Owen B. | Chief Scientific Officer | Exercise or conversion | 3K | $7.84 | $23K | 130K |
| 2020-07-01 | Cadavid Diego | SVP Clinical Development | Sell | 1K | $18.30 | $20K | 66K |
| 2020-06-30 | Wallace Owen B. | Chief Scientific Officer | Exercise or conversion | 141 | $7.84 | $1K | 127K |
| 2020-06-30 | Wallace Owen B. | Chief Scientific Officer | Sell | 141 | $20.00 | $3K | 127K |
| 2020-06-25 | Gould Robert J | See Remarks | Sell | 3K | $20.80 | $52K | 537K |
| 2020-06-25 | Cadavid Diego | SVP Clinical Development | Exercise or conversion | 1K | $4.83 | $7K | 68K |
| 2020-06-25 | Cadavid Diego | SVP Clinical Development | Sell | 1K | $22.00 | $32K | 67K |
| 2020-06-10 | Cadavid Diego | SVP Clinical Development | Sell | 401 | $22.00 | $9K | 67K |
| 2020-06-10 | Cadavid Diego | SVP Clinical Development | Exercise or conversion | 401 | $4.83 | $2K | 67K |
| 2020-06-09 | Gould Robert J | See Remarks | Sell | 156 | $20.00 | $3K | 540K |
| 2020-06-05 | Cadavid Diego | SVP Clinical Development | Exercise or conversion | 451 | $4.83 | $2K | 67K |
| 2020-06-05 | Cadavid Diego | SVP Clinical Development | Sell | 451 | $20.18 | $9K | 67K |
| 2020-06-05 | Gould Robert J | See Remarks | Sell | 3K | $20.17 | $69K | 540K |
| 2020-06-04 | Gould Robert J | See Remarks | Sell | 1K | $20.04 | $26K | 543K |
| 2020-06-04 | Cadavid Diego | SVP Clinical Development | Sell | 226 | $20.05 | $5K | 67K |
| 2020-06-04 | Cadavid Diego | SVP Clinical Development | Exercise or conversion | 226 | $4.83 | $1K | 67K |
| 2020-06-03 | Cadavid Diego | SVP Clinical Development | Exercise or conversion | 338 | $4.83 | $2K | 67K |
| 2020-06-03 | Cadavid Diego | SVP Clinical Development | Sell | 338 | $20.18 | $7K | 67K |
| 2020-06-03 | Gould Robert J | See Remarks | Sell | 2K | $20.13 | $30K | 545K |
| 2020-06-02 | Gould Robert J | See Remarks | Sell | 3K | $20.00 | $56K | 546K |
| 2020-06-02 | Cadavid Diego | SVP Clinical Development | Exercise or conversion | 45 | $4.83 | $217 | 67K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON5 Form 144 notices on file for FULC worth $54.8M at the prices reported; 1 in the last 90 days worth $54K. Latest: Greg Tourangeau filed on 2026-09-02 to sell 14,062 shares ($54K) from 2026-09-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-02 | Greg Tourangeauformer officer | 14K | $54K | 0.018% | 2026-09-02 | Merrill Lynch, Pierce, Fenner & Smith Inc |
| 2026-06-26 | ALAN EZEKOWITZDirector | 18K | $65K | 0.027% | 2026-06-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-15 | CURTIS G OLTMANSOfficer | 3K | $45K | 0.006% | 2025-12-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-08 | RA Capital Healthcare Fund LP10% Stockholder | 4.2M | $54.2M | 7.715% | 2025-12-08 | BTIG, LLC |
| 2025-11-19 | ROBERT J GOULDDirector | 45K | $438K | 0.083% | 2025-11-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON13 holders report 5% or more of FULC in their latest filing, all on Schedule 13G (passive). The largest reported stake is KEVIN TANG at 10.4% of the class (6,913,329 shares), filed 2026-07-15 for an event on 2026-07-13.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 7 | RA Capital Healthcare Fund, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 7 | RA Capital Management, L.P.investment adviser, partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 7 | Peter Kolchinskyparent holding company, individual | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 7 | Rajeev Shahparent holding company, individual | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Chen Yuindividual | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | TCG Crossover GP II, LLCother entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | TCG Crossover Fund II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G | Daniel Mackparent holding company | 5.5M | 8.2% | 2026-06-30 |
| 2026-08-14 | 13G | Wilmot B. Harkeyparent holding company | 5.5M | 8.2% | 2026-06-30 |
| 2026-08-14 | 13G | Nantahala Capital Management, LLCinvestment adviser | 5.5M | 8.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Montanova Capital, LLCinvestment adviser, other entity | 3.7M | 5.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Aaron Cowenparent holding company, individual | 3.7M | 5.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Averill Master Fund, Ltd.corporation | 2.6M | 3.8% | 2026-06-30 |
| 2026-08-03 | 13G | BANK OF AMERICA CORP /DE/parent holding company | 4.5M | 6.7% | 2026-06-30 |
| 2026-07-28 | 13G/Ano. 4 | BlackRock, Inc.parent holding company | 4.8M | 7.2% | 2026-06-30 |
| 2026-07-17 | 13G | BlackRock Portfolio Management LLCparent holding company | 4.0M | 6.0% | 2026-06-30 |
| 2026-07-15 | 13G/Ano. 1 | KEVIN TANGindividual | 6.9M | 10.4% | 2026-07-13 |
| 2026-07-15 | 13G/Ano. 1 | TANG CAPITAL MANAGEMENT, LLCother entity | 6.9M | 10.4% | 2026-07-13 |
| 2026-07-15 | 13G/Ano. 1 | TANG CAPITAL PARTNERS INTERNATIONAL, LPpartnership | 2.2M | 3.2% | 2026-07-13 |
| 2026-07-15 | 13G/Ano. 1 | TANG CAPITAL PARTNERS III, INCcorporation | 1.6M | 2.5% | 2026-07-13 |
| 2026-07-15 | 13G/Ano. 1 | TANG CAPITAL PARTNERS, LPpartnership | 1.6M | 2.5% | 2026-07-13 |
| 2026-07-15 | 13G/Ano. 1 | TANG CAPITAL PARTNERS IV, INCcorporation | 1.5M | 2.2% | 2026-07-13 |
| 2026-06-25 | 13G | Oleg Nodelmanparent holding company, individual | 6.0M | 9.0% | 2026-06-17 |
| 2026-06-25 | 13G | EcoR1 Capital, LLCinvestment adviser, other entity | 6.0M | 9.0% | 2026-06-17 |
| 2026-06-25 | 13G | EcoR1 Capital Fund Qualified, L.P.partnership | 5.6M | 8.4% | 2026-06-17 |
| 2026-03-26 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2025-11-13 | 13G/Ano. 2 | Adage Capital Management, L.P.investment adviser, partnership | 2.4M | 4.5% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 2 | Robert Atchinsonparent holding company, individual | 2.4M | 4.5% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 2 | Phillip Grossparent holding company, individual | 2.4M | 4.5% | 2025-09-30 |
13F holders
Tracked managers holding FULC at their latest 13F. JSON7 of the 30 tracked managers held FULC at their latest 13F, $41.9M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $11.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 3.0M | $11.1M | 0.01% | +1.4M |
| Citadel Advisors | 2026-06-30 | 2.7M | $9.9M | 0.00% | +1.4M |
| Renaissance Technologies | 2026-06-30 | 1.6M | $6.0M | 0.01% | +1.6M |
| Millennium Management | 2026-06-30 | 1.5M | $5.4M | 0.00% | +1.1M |
| AQR Capital Management | 2026-06-30 | 1.1M | $4.0M | 0.00% | +560K |
| Two Sigma Investments | 2026-06-30 | 813K | $3.0M | 0.00% | +674K |
| Point72 Asset Management | 2026-06-30 | 651K | $2.4M | 0.00% | -1.4M |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Fulcrum Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Fulcrum Therapeutics (FULC), SEC CIK 1680581, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-23.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-04.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-04-27.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-17.JSON and CSV
- Company record
- EDGAR filing index for CIK 1680581Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of FULC is sold short?
7,110,810 shares were held short at the 2026-09-30 settlement, 4.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is FULC's daily short volume?
On 2026-10-23, 98,257 of the 245,859 FULC shares reported to FINRA were sold short, 40.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does FULC have fails to deliver?
The SEC's latest file shows 15,212 FULC shares failed to deliver at settlement 2026-09-04. Fails are reported per settlement date and published twice a month with a lag.
Are FULC insiders buying or selling?
No open-market insider trades were reported for FULC in the last 90 days. The most recent filings are listed below. Latest filing: TANG KEVIN (10% owner) on 2026-07-17.
Have FULC insiders filed to sell?
5 Form 144 notices on file for FULC worth $54.8M at the prices reported; 1 in the last 90 days worth $54K. Latest: Greg Tourangeau filed on 2026-09-02 to sell 14,062 shares ($54K) from 2026-09-02.
Who owns 5% or more of FULC?
13 holders report 5% or more of FULC in their latest filing, all on Schedule 13G (passive). The largest reported stake is KEVIN TANG at 10.4% of the class (6,913,329 shares), filed 2026-07-15 for an event on 2026-07-13.
Which tracked 13F managers own FULC?
7 of the 30 tracked 13F managers held FULC shares at their latest filing, $41.9M in all. The largest: D. E. Shaw & Co. (3.0M shares, $11.1M), Ken Griffin's Citadel Advisors (2.7M shares, $9.9M), Renaissance Technologies (1.6M shares, $6.0M), Izzy Englander's Millennium Management (1.5M shares, $5.4M), Cliff Asness's AQR Capital Management (1.1M shares, $4.0M), Two Sigma Investments (813K shares, $3.0M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.